Turn Biotechnologies Acquires ARMMs Vesicular Technology to Increase Access to Tissue Targets for its Epigenetic Reprogramming Therapies
ARMMs brings precision medicine through targeted, non-viral vesicular delivery Synergy of ARMMs and eTurna™ LNP platforms means company can deliver broad range of larger, more varied cargoes – including gene editors, proteins and RNA-based therapies...
Turn Biotechnologies Announces Landmark Study to Assess Effectiveness of ERA™ Therapy in Restoring Bone Marrow
Researchers from Children's Hospital of Philadelphia (CHOP) seek to expand treatment access for patients MOUNTAIN VIEW, Calif., Dec. 3, 2024 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation and restoration company developing novel mRNA...